Covid-19 in a Patient with Congenital Analbuminemia and Coronary Artery Disease: A Case Report

¹Biochemistry Department, Military Hospital of Tunis, Monfleury, 1008, Tunis, Tunisia

²Biochemistry Laboratory, Bechir Hamza Children’s Hospital, Bab Saadoun Square, 1007, Tunis, Tunisia

³Department of Educational Sciences, Higher Institute of Applied Studies in Humanity Le Kef, University of Jendouba, Le Kef, Tunisia.

⁴Immunology Department, Military Hospital of Tunis, Monfleury, 1008, Tunis, Tunisia

⁵Anesthesiology Department, Bechir Hamza Children’s Hospital, Bab Saadoun Square, 1007, Tunis, Tunisia

*Corresponding author: Dr. Yessine Amri, Biochemistry Laboratory, Bechir Hamza Children’s Hospital, Bab Saadoun Square, Tunis 1007, Tunisia; Tel : 00216 22888506; E-mail: [email protected]

Received Date: February 6, 2023

Publication Date: February 13, 2023

Citation: Aboulkacem S, et al. (2023). Covid-19 in a Patient with Congenital Analbuminemia and Coronary Artery Disease: A Case Report. Mathews J Case Rep. 8(2):90.

Copyright: Aboulkacem S, et al. © (2023)

ABSTRACT

Congenital analbuminemia (CAA) is a very rare autosomal recessive disorder that can be rarely associated with coronary artery disease. Our data describe the clinical features and laboratory results of a COVID patient with congenital analbuminemia (CAA) and coronary artery disease. To the best of our knowledge, it is the first case of recurrent acute coronary syndrome in a young adult with CAA. Moreover, COVID-19 has never been described among the 90 cases of CAA reported in the literature. Mild clinical manifestations observed in such CAA patients can be explained by the elevated biosynthesis of other plasma proteins, including serum globulins. Indeed, the high serum complements C3 and C4 resulted from CAA disease protect patient from the risk of intravascular coagulation and cell death during COVID-19 infection. On the other hand, the statin therapy of hypercholesterolemia which is mostly observed in CAA patient reduce the incidence of severe clinical manifestations and improve prognosis in COVID-19 patients by modulating the immune response to inflammation, improving endothelial function, inhibiting oxidative stress, and exerting direct antiviral effects.

Keywords: Albumin; Congenital Analbuminemia; Coronary artery disease; COVID-19